
Feature|Videos|October 3, 2025
The Secrets of Successful Drug Launches: Cleaning Up Operations
Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, covers the five stages of the innovation process and how they can be used to improve operations.
Advertisement
Episodes in this series
Advertisement
Related to this article

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
Advertisement
Advertisement
Trending on PharmExec
1
Keeping Human Expertise at the Center of AI
2
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
3
Build, Buy, or Rent: Moving AI Beyond the Pilot Stage
4
Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir
5



